Evaluating omadacycline for treating diabetic foot infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and efficacy of omadacycline in hospitalized patients with moderate to severe diabetic foot infections (DFI) and acute osteomyelitis (AOM). It involves a prospective, open-label design across two centers, with enrollment of 57 patients alongside 114 historical controls. The study will collect data on the outcomes of patients treated with omadacycline compared to those receiving standard care, focusing on the risk of complications such as Clostridium difficile infection and acute kidney injury.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female and male subjects will be eligible for inclusion if hospitalized, 18 years or older, diagnosed with type 1 or 2 diabetes, and have DFI with the additional clinical criteria as specified below:

  * Acute infection or worsening without systemic antimicrobials within the previous 14 days
  * At least one full or partial thickness-infected ulcer at or below the ankle AND
  * Purulent drainage OR
  * Two of the following:

    * Erythema
    * Local edema
    * Fluctuance
    * Induration
    * Increased local warmth
    * Fever
  * No systemic antimicrobials with current hospital admission for more than 48 hours prior to enrollment
* Inclusion will be based on

  * Empiric coverage based on organisms suspected to be caused by susceptible bacteria, if no culture identifies a specific organism; or
  * Confirmed susceptibility to omadacycline against any organism identified. Any subject in which a pathogen resistant to omadacycline is identified will be excluded from the study and antibiotics will be changed based on physician discretion.

    * First episodes of AOM at qualifying site of infection will be eligible for inclusion with any of the following criteria confirming the diagnosis:

      * Imaging (X-ray or MRI) confirmation of acute osteomyelitis
      * Pathology (bone biopsy/culture)
    * Not currently enrolled in any other clinical trial
    * Provides informed consent
    * Likely to be compliant with all study-related procedures and visits

Exclusion Criteria:

* Age less than 18 years
* Pregnant women
* Chronic osteomyelitis

  * Osteomyelitis of the same site previously treated with antibiotics
  * Documented presence of osteomyelitis more than 2 weeks prior to index admission
  * Necrotic or dead bone identified by pathology
  * Unclear chronicity of infection (if unable to determine acute osteomyelitis)
* Has any gangrenous ulcers or necrotizing fasciitis
* Has a pathogen known to be resistant to omadacycline
* Administration of additional systemic antibiotics in combination with omadacycline, not including topical routes or oral vancomycin/fidaxomicin given their local activity within the GI tract
* Contraindication or hypersensitivity to omadacycline/tetracyclines
* Unwilling or unable to participate in study-related procedures or visits

Where it's running

• Methodist Dallas Medical Center
  Dallas, Texas, United States Recruiting
• Methodist Charlton Medical Center
  Dallas, Texas, United States Not yet recruiting

Study contacts

• Principal investigator: Matthew Crotty, PharmD — Methodist Health System
• Study coordinator: Crystee Cooper, DHEd
• Email: ClinicalResearch@mhd.com
• Phone: 214-947-1281

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Continuous temperature monitoring of the feet with connected insoles and a smartphone app in adults with diabetes at high risk

  This trial tests whether the Solsius SelfCare system can reliably flag pre-ulcer foot changes in adults with diabetes by detecting temperature differences between feet for at least two consecutive days.

  Recruiting at 2 sites Solsius · Lille and 2 other locations · NCT07910721

• Coordinated primary-care MDT approach for hard-to-heal ulcers

  A group of adults with hard-to-heal diabetic foot ulcers will be randomly assigned to standard care or a coordinated multidisciplinary team to see if the team approach helps ulcers heal better.

  Recruiting Nordsjaellands Hospital · Hillerød · NCT07747896

• Infrared thermal imaging of the diabetic foot in Guadeloupe

  This will test whether infrared thermal imaging shows different foot temperatures in healthy adults, people with diabetes, and people with diabetic foot ulcers in Guadeloupe.

  Recruiting Centre Hospitalier Universitaire de la Guadeloupe · Pointe-à-Pitre · NCT07040488

• Using stem cells from fat to treat diabetic foot ulcers

  This study is testing if using stem cells from fat, along with a special blood product, can help heal chronic foot ulcers in people with diabetes.

  Recruiting Phase 1 University of the Punjab · Lahore, Punjab Province · NCT05610865

• Comparing new antibiotics for treating diabetic foot infections

  This study is testing two new antibiotics to see if they can better treat moderate to severe foot infections in adults with diabetes compared to a standard antibiotic.

  Recruiting at 14 sites Phase 3 MicuRx · Corona, California and 13 other locations · NCT05369052

• Understanding biofilm infections in diabetic foot ulcers

  This study looks at how biofilm infections in diabetic foot ulcers affect healing and whether they make wounds more likely to come back.

  Recruiting at 2 sites University of Pittsburgh · Tucson, Arizona and 1 other locations · NCT05172089

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.